Prognostic value of LncRNA DLGAP1-AS2 in bladder cancer and its regulatory effect on tumor progression.

BACKGROUND

Bladder cancer (BLCA) represents one of the most prevalent malignant neoplasms within the urinary system, and its incidence is progressively rising annually in China.

OBJECTIVES

This research investigated the clinical significance of DLGAP1-AS2, and examined its potential mechanisms in modulating the behavior of BLCA cells.

METHODS

This study collected cancerous and normal tissue samples from 86 BLCA patients. qPCR was employed to assess DLGAP1-AS2 and miR-451a expression. Chi-square test was utilized to analyze the correlation between DLGAP1-AS2 and clinical parameters. Cox model and Kaplan-Meier analysis were conducted to evaluate the association between DLGAP1-AS2 and the prognosis of BLCA patients. Furthermore, DLGAP1-AS2 was silenced, both independently and jointly with miR-451a, in BLCA cell lines. CCK-8 assay assessed cell proliferation, and the Transwell assay evaluated cell migration and invasion capabilities.

RESULTS

DLGAP1-AS2 was elevated in BLCA tissues and exhibited a correlation with both smoking history and pathological features in BLCA patients. DLGAP1-AS2 was identified as a prognostic risk factor, wherein patients exhibiting low expression had a more favorable prognosis. DLGAP1-AS2 was up-regulated in BLCA cells, and its silencing led to a reduction in the proliferation, migration, and invasion of BLCA cells. Conversely, miR-451a was down-regulated in BLCA tissues and cells, and it demonstrated a negative regulatory interaction with DLGAP1-AS2. The concurrent silencing of DLGAP1-AS2 and miR-451a effectively restored the biological behaviors of BLCA cells.

CONCLUSION

DLGAP1-AS2 is a potential biomarker for evaluating the severity of BLCA and for predicting clinical prognosis. DLGAP1-AS2 regulates the malignant progression of BLCA via miR-451a.